Diabetic Foot Ulcer R&D Services
Diabetic foot represents one of the most severe and costly complications of diabetes. Globally, approximately 15-25% of individuals with diabetes develop diabetic foot ulcers during their lifetime. Ace Therapeutics provides preclinical translational research solutions for diabetic foot ulcers. Our integrated services include target validation, in vitro and in vivo disease modeling, preclinical efficacy evaluation, as well as biomarker discovery and translational support.
Introduction to Diabetic Foot Ulcer and Current Research Status
Diabetic foot ulcer, a common and challenging chronic complication of diabetes, involves complex pathogenesis primarily categorized into ischemic and neuropathic types. Current clinical management primarily employs debridement, antimicrobial therapy, revascularization, and glycemic control. While these approaches accelerate healing by promoting angiogenesis, improving glycemic levels, and reducing inflammation, they remain ineffective in preventing recurrence. Advancements in technologies like multi-omics and single-cell sequencing have led to breakthroughs in understanding the pathological mechanisms of diabetic foot ulcer. Preclinical studies using animal models play a pivotal role in elucidating mechanisms and evaluating therapeutic efficacy, providing crucial support for clinical translation.
Fig. 1 Advancements and best practices in diabetic foot care. (Kumbhar, Smita, and Manish Bhatia., 2024)
Our Diabetic Foot Ulcer R&D Services
Ace Therapeutics leverages our preclinical expertise and capabilities to help clients advance treatments for diabetic foot.
- Cell-level research: Investigate migration, proliferation, differentiation, and functional alterations in keratinocytes, fibroblasts, vascular endothelial cells, and immune cells (e.g., macrophages) under hyperglycemic conditions.
- Molecular pathway exploration: Employ molecular biology techniques to conduct in-depth analysis of key signaling pathways associated with inflammation, angiogenesis, and extracellular matrix remodeling.
- Pathogen Research: Identify and type common pathogens in diabetic foot ulcers (such as Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and anaerobic bacteria), analyze their antibiotic resistance profiles, and provide evidence for targeted anti-infective therapy.
Drug or diet-induced models: Mice/rats with type 1 and type 2 diabetes induced by streptozotocin or high-fat diet.
Wound creation: We provide full-thickness excision wounds, ischemic wounds (e.g., femoral artery ligation), and infectious wound models.
Gene editing models: Diabetic animals engineered with specific gene knockouts or overexpression using technologies such as CRISPR/Cas9 for target validation.
Minipig diabetic foot ulcer models provide anatomical and physiological similarities to human skin, making them suitable for evaluating medical devices and localized therapeutic strategies.
We provide comprehensive preclinical drug discovery and pharmacodynamic evaluation services, including but not limited to the following:
- Drug types: Preclinical development services for various therapies including small molecule drugs, biologics, cell therapies, and medical devices.
- Preclinical drug screening and efficacy evaluation: Comprehensive efficacy screening and validation of candidate drugs for diabetic foot ulcers using in vivo and in vitro models.
- Discovery and validation: We utilize tissue, blood, or wound exudate samples to identify potential biomarkers associated with the severity, prognosis, and treatment response of diabetic foot ulcers through proteomics, metabolomics, and other technologies.
- Assay development: We assist in developing rapid diagnostic tools based on ELISA, immunohistochemistry, or POCT.
Our Advanced Technology Platform
Our research platform is equipped with cutting-edge technologies to deliver robust and reliable data for our client's preclinical diabetic foot investigations.
| Technology Platform |
Introduction |
| High-Resolution Digital Wound Imaging and Analysis System |
Enable precise, non-invasive, and dynamic quantitative tracking of wound area. |
| Laser Doppler Perfusion Imager |
Objectively assess blood perfusion in the wound and surrounding tissues, providing a direct visualization of the efficacy of vascular regeneration. |
| Histopathology Platform, Immunohistochemistry or Immunofluorescence Platform |
We perform in-depth analysis of healing tissues to assess inflammatory cell infiltration, collagen deposition, vascular density, and specific protein expression. |
| In Vivo Imaging System |
Real-time tracking of cell migration, engraftment, and therapeutic drug distribution within the body. |
| Microbiology and Biofilm Research Platform |
Advanced imaging platforms (including SEM and confocal microscopy) enabling detailed characterization of biofilm structure and antimicrobial activity. |
Advantages of Our Diabetic Foot Ulcer R&D Services
- Highly customized solutions: We tailor research protocols to meet clients' specific requirements and R&D stages.
- Validated animal models: We maintain a stable and reliable library of diverse diabetic foot ulcer models, ensuring experimental data accuracy.
- Streamlined one-stop services: From model establishment and drug efficacy evaluation to biomarker analysis, we deliver end-to-end solutions that save clients time and accelerate development timelines.
The expert team at Ace Therapeutics looks forward to collaborating with you to help address challenges in diabetic foot research and development. Please feel free to contact us to discuss your specific project needs.
Reference
- Kumbhar, Smita, and Manish Bhatia. Advancements and best practices in diabetic foot care: A comprehensive review of global progress. Diabetes Research and Clinical Practice. 217 (2024): 111845.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
